Zogenix Sees Significant Decline in Short Interest (ZGNX)
Zogenix (NASDAQ:ZGNX) was the target of a large decrease in short interest in May. As of May 15th, there was short interest totalling 18,987,265 shares, a decrease of 6.3% from the April 30th total of 20,271,501 shares, Stock Ratings Network reports. Approximately 15.8% of the shares of the company are short sold. Based on an average daily volume of 1,534,907 shares, the days-to-cover ratio is presently 12.4 days.
A number of research firms have recently commented on ZGNX. Analysts at William Blair reiterated an “outperform” rating on shares of Zogenix in a research note on Monday, May 12th. They now have a $5.00 price target on the stock, down previously from $6.00. Analysts at Stifel Nicolaus reiterated a “buy” rating on shares of Zogenix in a research note on Friday, April 25th. They now have a $5.00 price target on the stock.
Shares of Zogenix (NASDAQ:ZGNX) opened at 2.01 on Wednesday. Zogenix has a one year low of $1.25 and a one year high of $5.19. The stock’s 50-day moving average is $2.36 and its 200-day moving average is $3.32. The company’s market cap is $280.5 million.
Zogenix (NASDAQ:ZGNX) last issued its quarterly earnings data on Thursday, May 8th. The company reported ($0.20) earnings per share for the quarter, missing the analysts’ consensus estimate of ($0.17) by $0.03. The company had revenue of $7.70 million for the quarter, compared to the consensus estimate of $8.71 million. During the same quarter last year, the company posted ($0.17) earnings per share. Zogenix’s revenue was up 10.0% compared to the same quarter last year. On average, analysts predict that Zogenix will post $-0.64 earnings per share for the current fiscal year.
Zogenix, Inc (NASDAQ:ZGNX) is a pharmaceutical company commercializing and developing products for the treatment of central nervous system disorders and pain.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.